Full-Time

Oncology Account Manager

Multiple Teams

Posted on 9/30/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$129.6k - $194.4k/yr

+ Bonus + Incentive Compensation + Equity Grants

Philadelphia, PA, USA

Remote

Home-based position in Pennsylvania.

Category
Sales & Account Management (1)
Requirements
  • Four-year college/university degree
  • Experience in Oncology
  • Excellent verbal and written communication skills with an effective presentation style both in face to face and virtual interactions to connect and build credibility with healthcare professionals
  • Ability to meet territorial travel requirements
Responsibilities
  • Direct promotion of Jazz Pharmaceuticals’ products
  • Development and management of business relationships with therapeutic specialists within an assigned geographical territory
  • Implement Jazz Pharmaceuticals’ marketing strategies and marketing tactics to achieve sales goals through short-term and long-term objectives
  • Keep the needs and expectations of the customer/patients at the forefront of all that we do
  • Define clear, measurable objectives that align both with the company goals and the goals and needs of the customer
  • Develop tailored strategies and tactics to address the unique needs and challenges of each customer
  • Continuously review and adjust the strategic account plan based on activities, feedback, changing market conditions and evolving customer needs
  • Engage and align with cross-functional partners to mobilize resources and ideas to deliver to successfully meet customer and patient needs
  • Effective promotion of Jazz Pharmaceuticals Adult Oncology products to physicians and other health care providers within the designated area at both community and Academic centers
  • Educate physicians and other health care professionals about Jazz Pharmaceuticals product(s)
  • Utilize CRM tools to effectively manage customer interactions, track sales activities and maintain accurate territory records
  • Participate in organizing and facilitating meetings for the exchange of medical and product information in line with the company’s policies, regulatory and legal requirements
Desired Qualifications
  • Post-graduate business school study, training
  • Minimum of 5 years in the oncology market
  • Strong clinical, technical and scientific knowledge of product(s); applicable disease states desired
  • Strategic thinker who can drive a strategic account business plan
  • Strong key account management experience working in complex academic and community accounts
  • Demonstrated history of strong business acumen, problem solving, effective prioritization, account management and effective sales data analytics skills
  • Skillful in fostering teamwork and collaboration in cross-functional account management
  • Results oriented with a proactive and Self-motivated approach to driving sales growth
  • Experience with GI, HER2 landscape, biomarker driven therapeutics and/or Lung Cancer highly preferred
  • Key Account & Market dynamics knowledge

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Xywav and Epidiolex continue driving double-digit neuroscience revenue growth.
  • Zepzelca's first-line SCLC uptake expands Jazz's oncology franchise rapidly.
  • Chimerix adds dordaviprone, strengthening the late-stage rare-brain-cancer pipeline.

What critics are saying

  • Oxybate franchise concentration exposes revenue to payer pressure and competitive switching.
  • Epidiolex growth slows if adult and long-term-care adoption disappoints.
  • Oncology upside depends on continued Zepzelca and zanidatamab execution.

What makes Jazz Pharmaceuticals unique

  • Rare-disease focus spans neuroscience and oncology with limited-treatment options.
  • Jazz built growth through acquisitions like GW Pharmaceuticals, Celator, and Chimerix.
  • Dublin incorporation and global footprint support cross-border operations and tax optimization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE